NASDAQ$NVAX

Novavax Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Reported a net loss due to increased research and development expenses, but revenue increased due to NVX-CoV2373 development activities.

Novavax reported a net loss of $352 million for the second quarter of 2021, compared to a net loss of $18 million for the same period in 2020. Revenue increased to $298 million, driven by increased development activities related to NVX-CoV2373. The company had $2.1 billion in cash, cash equivalents and restricted cash as of June 30, 2021.

  • Net loss was $352 million, or $4.75 per share.
  • Revenue increased to $298 million due to NVX-CoV2373 development.
  • Research and development expenses increased to $571 million.
  • Cash, cash equivalents and restricted cash totaled $2.1 billion as of June 30, 2021.

Headline financials

Total Revenue

$298M

Previous: $35.5M+738.6%
EPS (adj)

-$4.75

Previous: -$0.30-1483.3%
Free Cash Flow

-$352M

Previous: -$17.5M-1910.8%
Net Income

-$352M

Previous: -$17.5M-1910.8%
Operating Income

-$346M

Previous: -$17M-1931.1%
Gross Profit

$298M

Previous: $35.5M+738.6%
Cash & Equivalents

$2.07B

Previous: $424M+388.9%
Total Assets

$2.75B

Previous: $932M+194.9%
Stock-Based Comp

$53.1M

Previous: $7.93M+569.7%

Revenue & EPS history

Novavax · Revenue · Quarterly

$298M

Q2 2021+738.6%vs Q2 2020
Beat estimate in 4 of 16 quarters(25%)
ActualEstimate

Revenue by segment

Novavax · $2.23M total across 1 segment · Q3 2023

  • Product sales
    $2.23M

Forward guidance

Forward-looking statements include risks related to satisfying regulatory requirements, obtaining scarce raw materials, resource constraints, and meeting contractual requirements.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+2.5%

Avg return

Earnings day

+5.0%

Avg return

5 days after

+11.8%

Avg return

30 days after

36%

23 / 64 earnings

Positive

+193.3%

Q1 2024

Best reaction

-33.2%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+15.6%+17.3%+17.0%
Q4 2025+0.5%-0.4%-11.3%
Q3 2025-3.0%-3.3%-10.1%
Q1 2025+11.6%+4.0%+25.2%
Q4 2024-3.6%+4.9%-4.4%
Q3 2024-13.8%-18.8%+0.1%
Q2 2024+8.3%+13.5%+8.6%
Q1 2024+193.3%+188.6%+306.5%
Q4 2023-17.9%-8.8%-20.6%
Q3 2023-8.2%-8.2%-18.1%
Q2 2023-5.3%-2.1%+21.7%
Q1 2023+20.7%+13.4%+3.2%
Q4 2022-20.9%-11.3%-24.0%
Q3 2022-4.1%+28.9%-10.9%
Q2 2022-33.2%-31.2%-49.2%
Q1 2022-6.0%-9.4%-12.5%
Q4 2021+2.6%-12.1%-8.4%
Q3 2021-18.4%-13.3%-17.8%
Q2 2021-15.2%+2.9%+12.4%
Q1 2021-21.5%-25.2%+19.1%
Q4 2020-10.9%-24.4%-21.6%
Q3 2020-12.4%+7.5%+28.2%
Q2 2020-12.2%-14.0%-46.7%
Q1 2020+112.6%+132.9%+140.0%
Q4 2019-12.8%-35.1%+60.1%
Q3 2019+3.8%-6.3%-1.6%
Q2 2019-8.2%-15.5%+15.5%
Q1 2019-7.8%-21.6%-44.3%
Q4 2018+7.8%+5.9%+3.9%
Q3 2018-3.7%-10.5%+7.3%
Q2 2018+22.5%+13.3%+24.2%
Q1 2018-1.2%+4.3%-1.2%
Q4 2017-4.2%-2.8%-15.3%
Q3 2017+0.9%+0.0%+24.8%
Q2 2017+3.1%+4.2%+22.9%
Q1 2017+14.9%+35.1%+43.2%
Q4 2016+9.4%+6.5%-7.2%
Q3 2016-3.4%-6.9%+0.7%
Q2 2016-9.2%-6.4%-0.3%
Q1 2016-8.9%
Q4 2015-0.2%
Q3 2015-12.2%
Q2 2015+28.3%
Q1 2015+4.4%
Q4 2014-1.9%
Q3 2014-7.2%
Q2 2014-5.0%
Q1 2014-7.1%
Q4 2013-0.8%
Q3 2013+3.2%
Q2 2013-10.8%
Q1 2013-8.9%
Q4 2012-0.5%
Q3 2012-1.8%
Q2 2012+0.5%
Q1 2012-5.7%
Q4 2011+0.0%
Q3 2011+0.0%
Q2 2011+5.9%
Q1 2011+0.4%
Q4 2010+0.0%
Q3 2010+1.3%
Q2 2010-1.3%
Q1 2010+14.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro